Literature DB >> 22470074

Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: retrospective chart analysis of a prospective database.

Xavier M Keutgen1, Daniel Buitrago, Filippo Filicori, Anna Kundel, Olivier Elemento, Thomas J Fahey, Rasa Zarnegar.   

Abstract

OBJECTIVE: This study aims to determine the efficacy of calcimimetics in improving bone mineral density (BMD) in patients with primary hyperparathyroidism (pHPT) and compare those results to patients undergoing parathyroidectomy.
BACKGROUND: Parathyroidectomy has been shown to improve BMD in pHPT, but calcimimetics have recently been advocated as a medical alternative to parathyroidectomy for pHPT.
MATERIALS AND METHODS: We identified 17 patients that were treated with calcimimetics for pHPT. Seventeen patients with pHPT who underwent parathyroidectomy served as surgical controls. Serum calcium level, parathyroid hormone (PTH) level, and femur and spine BMD T scores were compared before and 1 year after therapy.
RESULTS: Both groups were demographically matched. Calcium levels normalized in 70.6% of medically versus 100% of surgically treated patients (P = 0.026). PTH levels normalized in 35% of patients treated with calcimimetics versus 76% of surgical patients (P = 0.036). Femur BMD improved in 18.8% of medically treated patients versus 58.8% of surgical patients (P = 0.032). Spine BMD improved in 70.6% of medically treated patients versus 82.4% of surgical patients (P = 0.69). Further analysis demonstrated that regardless of treatment, normalization of PTH was associated with significant improvement in femur (P = 0.03) and spine BMD (P < 0.001). Normalization of calcium without normalization of PTH did not impact BMD.
CONCLUSIONS: Parathyroidectomy results in greater normalization of serum calcium and PTH levels and significantly improves cortical BMD compared to calcimimetics. Regardless of treatment, normalization of PTH is associated with significant improvement in spine and femur BMD, suggesting that the superior effects of surgery may be mediated by better control of PTH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22470074     DOI: 10.1097/SLA.0b013e31824c5252

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  7 in total

Review 1.  Primary Hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

Review 2.  Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism.

Authors:  Barbara C Silva; John P Bilezikian
Journal:  Rev Endocr Metab Disord       Date:  2020-11-16       Impact factor: 6.514

3.  Skeletal effects of combined bisphosphonates treatment and parathyroidectomy in osteoporotic patients with primary hyperparathyroidism.

Authors:  Hun Jee Choe; Bo Kyung Koo; Ka Hee Yi; Sung Hye Kong; Jung Hee Kim; Chan Soo Shin; Jee Won Chai; Sang Wan Kim
Journal:  J Bone Miner Metab       Date:  2021-11-10       Impact factor: 2.626

Review 4.  Primary hyperparathyroidism.

Authors:  John P Bilezikian; Natalie E Cusano; Aliya A Khan; Jian-Min Liu; Claudio Marcocci; Francisco Bandeira
Journal:  Nat Rev Dis Primers       Date:  2016-05-19       Impact factor: 52.329

Review 5.  The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies.

Authors:  Manju Chandran; John P Bilezikian; Joel Lau; Reshma Rajeev; Samantha Peiling Yang; Miny Samuel; Rajeev Parameswaran
Journal:  Rev Endocr Metab Disord       Date:  2022-01-18       Impact factor: 9.306

Review 6.  Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review.

Authors:  Julius Simoni Leere; Jesper Karmisholt; Maciej Robaczyk; Peter Vestergaard
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-20       Impact factor: 5.555

Review 7.  Role of Calcimimetics in Treating Bone and Mineral Disorders Related to Chronic Kidney Disease.

Authors:  Yi-Chou Hou; Cai-Mei Zheng; Hui-Wen Chiu; Wen-Chih Liu; Kuo-Cheng Lu; Chien-Lin Lu
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.